Where a Beauty Device Stops Being a Beauty Device: The EU Claim Boundary Importers Must Map
The line between cosmetic and medical device in the EU hinges on label wording, not just function—terms like skin renewal or anti-wrinkle can shift regulatory class, requiring importers to audit claims against MDR and cosmetic rules before placing any light-therapy product on the market.
For the AOM807 fourth-generation NIR milk-light device with IPX0 rating, 220 V/60 W mains power and sapphire hot/cold head, the manufacturer lists functions including brightening, hydrating, spot-fading, anti-wrinkle, skin renewal and lifting in a gold housing with gift box packaging. These terms are not neutral descriptors; under EU Regulation 2017/745, phrases such as skin renewal or anti-wrinkle may imply a therapeutic effect on skin structure or function, pushing the product toward medical device classification if presented as intended purpose. Importers must therefore treat the label’s intended purpose as the legal starting point, not the underlying LED or NIR technology itself, which could be 610–1200 nm for IPL or narrower bands for LED photobiomodulation. The safety standard question—whether the device meets IEC 60601-1 or IEC 62471 for optical radiation—is distinct from the claim boundary analysis; a product can be electrically safe yet still fall under MDR if its labelling suggests diagnosis, treatment or prevention of disease. Conversely, a device with identical hardware but labelled only for temporary hydration or general skin brightening may remain within the cosmetic scope defined by Regulation (EC) No 1223/2009, provided no claims go beyond altering skin appearance without affecting physiology. This distinction is critical for importers because misclassification triggers different obligations: medical devices require CE marking under MDR, clinical evidence, technical documentation reviewed by a notified body, and post-market surveillance, while cosmetics need only CPNP notification and compliance with restricted substance lists. Buyers should request the supplier’s intended purpose statement in writing and verify it against the final label language before customs clearance, as national authorities in Germany, France or Italy may interpret borderline claims differently based on local guidance documents.
Conduct a claim-word audit by mapping each function on the AOM807 label to its regulatory implication—brightening and hydrating typically stay cosmetic, but spot-fading may edge toward medical if linked to melanin reduction as a therapeutic outcome, and anti-wrinkle or skin renewal often imply collagen stimulation or dermal repair, which falls under MDR Annex I. Lifting, when tied to muscle tone improvement via EMS, could invoke both MDR and the PPE Regulation if neuromuscular stimulation is claimed. Importers must not assume that CE marking alone covers all regimes; the device might need separate conformity assessments for electrical safety, optical emission and medical intent. Always consult the latest EU Commission guidance on borderline products and national competent authority positions, as the applicable framework depends on the exact wording approved for sale, not the manufacturer’s internal catalogue.
For distributors and spa buyers sourcing the AOM807 or similar light-therapy devices from Aolemon, the imperative is to treat label wording as the regulatory switchpoint—never assume similarity in hardware equals similarity in legal status. Request documented intended purpose from the supplier, cross-check it against the final EU-facing label, and confirm whether the claimed effects remain within cosmetic boundaries or require MDR compliance. Only then can you secure market access without risking non-compliance actions, recalls or reputational damage across the EU’s fragmented but vigilant national surveillance systems.